Meireles Camilla Barros, Maia Laís Chaves, Soares Gustavo Coelho, Teodoro Ilara Parente Pinheiro, Gadelha Maria do Socorro Vieira, da Silva Cláudio Gleidiston Lima, de Lima Marcos Antonio Pereira
Laboratory of Microbiology and Parasitology, Faculty of Medicine, Federal University of Cariri, UFCA, Barbalha, Ceará, Brazil.
Center for Biological and Health Sciences, Regional University of Cariri, URCA, Crato, Brazil.
Acta Trop. 2017 Aug;172:240-254. doi: 10.1016/j.actatropica.2017.05.022. Epub 2017 May 17.
Cutaneous Leishmaniasis (CL) is endemic in 88 countries, showing relevant prevalences. The aim of this study was to perform a systematic review on atypical lesions of CL around the world, addressing clinico-epidemiological, immunological and therapeutic aspects. A search of the literature was conducted via electronic databases Scopus and PubMed for articles published between 2010 and 2015. The search terms browsed were "cutaneous leishmaniasis", "atypical" and "unusual". Based on the eligibility criteria, 34 out of 122 articles were included in the final sample. Atypical lesions may include the following forms: erythematous volcanic ulcer, lupoid, eczematous, erysipeloid, verrucous, dry, zosteriform, paronychial, sporotrichoid, chancriform and annular. In any cases, they seem to be another disease like subcutaneous and deep mycosis, cutaneous lymphoma, pseudolymphoma, basal and squamous cell carcinoma. The lesions have been reported in the face, cheeks, ears, nose, eyelid, limbs, trunk, buttocks, as well as in palmoplantar and genital regions; sometimes occurring in more than one area. The reason for clinical cutaneous leishmaniasis pleomorphism is unclear but immunosuppression seems to play an important role in some cases. There are no established guidelines for the treatment of atypical cutaneous leishmaniasis. However, pentavalent antimonials remain as first line treatment for all forms of leishmaniasis even for HIV-infected patients and atpical forms. Finally, to diagnose an atypical lesion properly, the focus has to be on the medical history and the origin of the patient, comparing them to the natural history of leishmaniasis and always reminding of possible atypical presentations, to then start searching for the best diagnostic method and treatment, reducing the misdiagnosis rate and, subsequently, controlling the disease progression. Thereby, contributing for breaking the transmission chain of the parasite, due to early correct diagnosis which, in turn, contributes to reduce the prevalence.
皮肤利什曼病(CL)在88个国家呈地方性流行,具有较高的患病率。本研究的目的是对世界各地CL的非典型病变进行系统评价,涉及临床流行病学、免疫学和治疗方面。通过电子数据库Scopus和PubMed检索2010年至2015年发表的文章。检索词为“皮肤利什曼病”、“非典型”和“不寻常”。根据纳入标准,最终样本纳入了122篇文章中的34篇。非典型病变可能包括以下形式:红斑性火山口溃疡、狼疮样、湿疹样、丹毒样、疣状、干燥型、带状疱疹样、甲沟炎样、孢子丝菌病样、下疳样和环状。在任何情况下,它们似乎都是另一种疾病,如皮下和深部真菌病、皮肤淋巴瘤、假性淋巴瘤、基底细胞癌和鳞状细胞癌。这些病变已在面部、脸颊、耳朵、鼻子、眼睑、四肢、躯干、臀部以及掌跖和生殖器区域被报道;有时会出现在多个区域。临床皮肤利什曼病多形性的原因尚不清楚,但免疫抑制在某些情况下似乎起着重要作用。目前尚无针对非典型皮肤利什曼病治疗的既定指南。然而,五价锑制剂仍然是所有形式利什曼病的一线治疗药物,即使是对HIV感染患者和非典型形式。最后,为了正确诊断非典型病变,必须关注病史和患者的来源,将它们与利什曼病的自然病史进行比较,并始终牢记可能的非典型表现,然后开始寻找最佳的诊断方法和治疗方法,降低误诊率,进而控制疾病进展。从而有助于打破寄生虫的传播链,因为早期正确诊断反过来有助于降低患病率。